Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-05-22 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2021 Annual General Meeting (AGM) of Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions on the meeting's validity. The content focuses on the outcomes of shareholder votes on various proposals including financial reports, board reports, and company bylaws amendments. It does not contain the full annual report or financial statements but rather the official voting results and resolutions passed at the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at general meetings. The document length is about 5006 characters, and it is not merely an announcement of a report but the actual voting results from the AGM. Therefore, the correct classification is DVA with high confidence.
2022-05-22 Chinese
关于收到北京证券交易所对公司 2021 年年度报告问询函的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Yunnan Shengwu Gu Pharmaceutical Co., Ltd. regarding the receipt of an inquiry letter from the Beijing Stock Exchange about the company's 2021 Annual Report. The content includes detailed questions and requests for explanations about various financial and operational aspects of the 2021 Annual Report, such as revenue, sales expenses, accounts receivable, construction in progress, investments, R&D expenses, inventory, financial assets, and other matters. The document does not contain the actual annual report or financial statements but is a regulatory inquiry letter seeking clarifications and additional disclosures related to the annual report. The document length is 4456 characters, which is relatively short and consistent with an announcement or inquiry rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement related to the annual report inquiry, not the annual report itself or an audit report.
2022-05-19 Chinese
关于公司收到中国证券监督管理委员会云南监管局行政监管措施决定书的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from a company regarding an administrative regulatory measure decision issued by the China Securities Regulatory Commission (CSRC) Yunnan Bureau. It details the regulatory action taken against the company for violations related to shareholder fund occupation, the legal basis for the penalty, the company's response and remediation measures, and the impact assessment. The document does not contain financial statements or detailed financial performance data but is a regulatory announcement about a legal/regulatory proceeding and compliance measures. It is not an annual report, audit report, earnings release, or any financial report. It fits best under Legal Proceedings Report (LTR) as it updates on significant regulatory actions involving the company.
2022-05-19 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" (Investor Relations Activity Record) and specifically mentions it is an "业绩说明会" (Performance Explanation Meeting) related to the 2021 Annual Report. The content includes a Q&A session where company management answers investor questions about company performance, strategy, product development, and financial results. The document is about a meeting held on May 18, 2022, to explain the annual report results, which fits the definition of a Call Transcript (CT) as it is a full text transcript of a company conference call or investor meeting discussing financial results and company outlook. The document length is 3860 characters, which is typical for a transcript rather than a full annual report. It is not a report publication announcement or a regulatory filing. Therefore, the best classification is Call Transcript (CT).
2022-05-17 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the unusual stock price movements over specific recent trading days, the company's investigation into potential causes, and a statement confirming no undisclosed material information affecting stock price. It also includes a risk warning to investors. The document is regulatory in nature, focused on stock price behavior and disclosure compliance, without financial statements or detailed financial data. It is not an annual report, earnings release, or any financial report but a regulatory announcement about stock trading activity and company disclosures. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (1720 characters), consistent with a regulatory announcement rather than a full report.
2022-05-15 Chinese
华融证券关于北京证券交易所对生物谷问询函的回复
Regulatory Filings Classification · 95% confidence The document is a detailed response to an inquiry letter from the Beijing Stock Exchange regarding the company's (Yunnan Shengwu Gu Pharmaceutical Co., Ltd.) related party fund occupation issues, internal control deficiencies, and governance matters. It includes extensive investigation procedures, findings, internal control weaknesses, corrective measures, and ongoing supervision by the sponsoring institution (Huarong Securities). The document references the 2021 annual report and other governance disclosures but is itself a standalone inquiry response and governance investigation report. It does not contain full financial statements or quarterly results but focuses on governance, internal control, and regulatory compliance issues related to fund occupation and related party transactions. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory response and compliance disclosure rather than a full annual report, audit report, or management report. The document length (11,655 characters) and detailed content support this classification with high confidence.
2022-05-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.